Medicenna Therapeutics Corp (TSE:MDNA)
TSX:MDNA
Top Page
Medicenna Therapeutics Corp
(TSX:MDNA)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.60
▼(-30.81% Downside)
Action:ReiteratedDate:02/18/26
The score is primarily weighed down by weak financial performance (pre-revenue, ongoing losses and negative free cash flow with shrinking equity/assets) and bearish technicals (below major moving averages with negative momentum). Valuation is also constrained by the negative P/E and lack of dividend support.
Positive Factors
Platform-based cytokine engineering
Medicenna’s platform engineering approach is a durable competitive asset: designing next‑generation IL and cytokine candidates can produce multiple differentiated assets with improved efficacy/toxicity profiles. A reusable platform can lower per‑asset discovery risk, enable follow‑on programs and attract partners over multiple development cycles.
Negative Factors
Sustained negative operating and free cash flow
Consistent negative operating and free cash flow indicate the company cannot self‑fund development. Persistent burn (~-C$18.4M OCF TTM) forces recurring external financing or partnerships, increasing dilution risk and possibly delaying programs if capital terms deteriorate over the typical multi‑year clinical development horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform-based cytokine engineering
Medicenna’s platform engineering approach is a durable competitive asset: designing next‑generation IL and cytokine candidates can produce multiple differentiated assets with improved efficacy/toxicity profiles. A reusable platform can lower per‑asset discovery risk, enable follow‑on programs and attract partners over multiple development cycles.
Read all positive factors
Medicenna Therapeutics Corp (MDNA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$42.61M
Dividend YieldN/A
Average Volume (3M)30.62K
Price to Earnings (P/E)―
Beta (1Y)1.76
Revenue GrowthN/A
EPS Growth54.74%
CountryCA
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding68,726,980
10 Day Avg. Volume37,956
30 Day Avg. Volume30,624
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)24.28
Price to Sales (P/S)0.00
P/FCF Ratio-7.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.35
Revenue Forecast (FY)C$895.83K
Medicenna Therapeutics Corp Business Overview & Revenue Model
Company Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC...
How the Company Makes Money
null...
Medicenna Therapeutics Corp Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -58.00K | -55.00K | -5.00K | -38.00K | -40.00K | -6.82K |
| EBITDA | -21.65M | -12.97M | -18.67M | -22.54M | -17.25M | -4.70M |
| Net Income | -12.99M | -11.80M | -25.47M | -22.65M | -17.18M | -4.71M |
Balance Sheet | ||||||
| Total Assets | 13.06M | 28.38M | 19.13M | 23.46M | 42.25M | 5.19M |
| Cash, Cash Equivalents and Short-Term Investments | 10.61M | 24.84M | 16.98M | 20.54M | 40.38M | 2.37M |
| Total Debt | 205.00K | 168.00K | 0.00 | 0.00 | 34.00K | 0.00 |
| Total Liabilities | 6.85M | 9.29M | 13.94M | 2.62M | 4.11M | 2.57M |
| Stockholders Equity | 6.21M | 19.09M | 5.19M | 20.84M | 38.15M | 2.62M |
Cash Flow | ||||||
| Free Cash Flow | -13.48M | -16.52M | -16.26M | -23.58M | -15.31M | -8.04M |
| Operating Cash Flow | -18.44M | -16.49M | -16.26M | -23.58M | -15.31M | -8.04M |
| Investing Cash Flow | 2.00K | -33.00K | 0.00 | 10.05M | 5.01M | -354.46K |
| Financing Cash Flow | -18.00K | 23.49M | 0.00 | 3.88M | 18.26M | 6.82M |
Medicenna Therapeutics Corp Technical Analysis
Negative
0.86
Price Trends
0.81
Negative
1.01
Negative
1.01
Negative
Market Momentum
-0.06
Positive
32.19
Neutral
28.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDNA, the sentiment is Negative. The current price of 0.86 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.81, and below the 200-day MA of 1.01, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 32.19 is Neutral, neither overbought nor oversold. The STOCH value of 28.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MDNA.
Medicenna Therapeutics Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | C$50.54M | 95.68 | 3.31% | ― | 5.29% | -29.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | C$171.86M | -4.57 | -51.42% | ― | ― | 27.53% | |
42 Neutral | C$42.61M | -4.40 | -103.51% | ― | ― | 54.74% | |
39 Underperform | C$40.16M | -12.93 | 72.34% | ― | ― | 10.49% |
* Healthcare Sector Average
TSE:MDNA
Medicenna Therapeutics Corp
0.62
-0.31
-33.33%
TSE:MSCL
Satellos Bioscience
8.25
0.45
5.78%
TSE:ARCH
Arch Biopartners
0.60
-0.96
-61.54%
TSE:COV
Covalon Technologies
1.83
-0.34
-15.67%
TSE:METX
ME Therapeutics Holdings, Inc.
2.50
-7.50
-75.00%
TSE:ONCO
Onco-Innovations Ltd.
1.47
-0.10
-6.37%
Medicenna Therapeutics Corp Corporate Events
Business Operations and StrategyProduct-Related Announcements
Medicenna to Showcase First-in-Class Tumor-Targeted PD-1 x IL-2 Superkine at AACR 2026
Positive
Mar 18, 2026
Medicenna Therapeutics will present updated preclinical data at the AACR Annual Meeting 2026 on MDNA113, a first-in-class, tumor-targeted and conditionally activated anti-PD-1-IL-2 bifunctional Superkine designed to anchor in IL-13Rα2-overexp...
Business Operations and Strategy
Medicenna to Spotlight Superkine Oncology Pipeline at Global Investor and Scientific Conferences
Positive
Feb 18, 2026
Medicenna Therapeutics will spotlight its Superkine-based immunotherapy programs at a series of upcoming industry and investor conferences across the U.S. and Europe. The company aims to deepen engagement with scientific, clinical and financial st...
Business Operations and StrategyExecutive/Board Changes
Medicenna Refreshes Board With Capital Markets and Biotech Leadership Expertise
Positive
Feb 13, 2026
Medicenna Therapeutics has reshaped its board of directors by appointing Richard Sutin and Angelos Georgakis, effective February 12, 2026, while longtime director Karen Dawes retires from the board and transitions to a consulting role. The company...
Business Operations and StrategyProduct-Related Announcements
Medicenna Maps 2026 Milestones as IL-2 Superkine MDNA11 Delivers Promising Cancer Responses
Positive
Jan 15, 2026
Medicenna reported updated clinical data for its lead IL-2 super agonist MDNA11 from the ongoing Phase 1/2 ABILITY-1 trial, showing encouraging objective response rates in heavily pretreated cancer patients, particularly in the second- and third-l...
Business Operations and StrategyFinancial Disclosures
Medicenna Targets Pivotal 2026 as IL-2 Superkine Programs Advance Toward Registrational Trials
Positive
Jan 15, 2026
Medicenna Therapeutics outlined a potentially pivotal 2026 as it advances its Superkine immunotherapy pipeline, led by IL-2 super agonist MDNA11 and conditionally activated bifunctional anti-PD1–IL-2 candidate MDNA113. Updated data from the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.